Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Moderna

Here's Why Moderna Shares Are Trading Higher After Q1 Earnings Today

Moderna Inc (NASDAQ:MRNA) reports a Q1 EPS of $8.58, compared to the $2.84 posted a year ago, handsomely beating the consensus estimate of $5.21. Total revenue was $6.1 billion compared to $1.9 billion in Q1 FY21, primarily due to increased product sales. The revenue consensus was $4.43 billion. Product sales were $5.9…

Benzinga

Moderna: Q1 Earnings Insights

Moderna (NASDAQ:MRNA) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Benzinga

Pfizer hopes to submit little-kid vaccine data by early June

Pfizer now hopes to tell U.S. regulators how well its COVID-19 vaccine works in the littlest kids by early June

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer accused of Covid profiteering as first-quarter sales hit $26bn

Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill

The Guardian - UK

Moderna Bullish On COVID-19 Vaccine For Younger Kids To Be Ready Next Month: Reuters

Moderna Inc's (NASDAQ:MRNA) chief medical officer said that its COVID-19 vaccine for children under six years old would be ready for review by the FDA panel when it meets in June. "I think the FDA now has all of the core fundamental data they need to be able to begin an application review.…

Benzinga

Here's What To Watch On Moderna As The Stock Flies Higher

Moderna, Inc (NASDAQ: MRNA) was trading over 8% higher at one point on Monday morning, bouncing up within a descending channel pattern on the daily chart.

Benzinga

American Express And 2 Other Stocks Insiders Are Selling

Gold futures traded lower by around 2.5% on Monday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Pressure builds for COVID vaccines approval for littlest kids

Moderna's request for approval of its COVID -19 vaccine in children under six years amps up pressure on the Food and Drug Administration to act quickly to approve the shots.

Axios

Chinese Omicron-specific mRNA COVID vaccine candidate to be trialed in UAE

China's Suzhou Abogen Biosciences Co said its COVID-19 vaccine candidate using the messenger RNA (mRNA) technology and targeting the Omicron variant has obtained clinical trial approval in the United Arab Emirates.

Reuters

FDA Sets Review Dates For Pfizer, Moderna COVID-19 Shot For Kids, Plus Novavax EUA

The FDA has set up June meeting dates to review COVID-19 vaccine submissions, noting that the dates are tentative as none of the submissions are complete. The agency reserved June 8, 21, and 22 for virtual meetings of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) to review Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE)…

Benzinga

FDA sets June meetings on COVID vaccines for youngest kids

The Food and Drug Administration has set tentative dates in June to publicly review COVID-19 vaccines for the youngest American children

The Independent UK

Scottish campaigners protest at Pfizer office as 'vaccine equity' motion voted down

CAMPAIGNERS from Global Justice Now Scotland have stated they are “outraged” as shareholders at pharmaceutical multinationals Pfizer and Moderna…

The National (Scotland)

Moderna Seeks FDA Emergency Use Nod For COVID-19 Shot In Kids 2-6 Years

Moderna Inc (NASDAQ: MRNA)

Benzinga

Moderna seeks FDA approval of Covid vaccine for children aged six months to five years old

The request arrives one month after the drug company said its two-dose jabs provided immune protection in youngest children

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Evening Standard

Covid vaccine: Moderna seeks US approval for jab for kids under 6

Trials showed the jab was 37 per cent effective for two and five-year-olds and 51 per cent for children between six months and the age of two

Tribune News Service

Moderna applies for US clearance of COVID shot for young kids

Moderna Inc. applied for emergency use authorization for its COVID-19 vaccine in children from six months to under 6 years old after a successful trial showed two doses generate high levels of antibodies to the virus.

Benzinga

The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates

Here's a roundup of top developments in the biotech space over the last 24 hours:

The Independent UK

Moderna seeks to be 1st with COVID shots for littlest kids

Moderna is asking U.S. regulators to open its COVID-19 vaccine to the nation's youngest children

Get all your
news in one place.

100’s of premium titles.
One news app.

Axios

Moderna seeks emergency authorization for COVID-19 vaccine in young children

Moderna said last month its vaccine for kids generated a strong immune response.

Roll Call

Moderna asks FDA to authorize COVID-19 vaccine for kids under 6 - Roll Call

Moderna said Thursday that it asked the FDA for emergency use authorization of its COVID-19 vaccine in kids under age 6.

Salon

Another delay for five-and-under vaccine

The issue isn't around safety, but instead messaging and vaccine effectiveness

Roll Call

Most Americans have COVID-19 antibodies as case numbers rise - Roll Call

The percentage of people with antibodies increased from 34 percent in December to roughly 58 percent in February, the CDC said.

Benzinga

Moderna Whale Trades For April 26

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

The Conversation

How Robert Langer, a pioneer in delivering mRNA into the body, failed repeatedly but kept going: 'They said I should give up, but I don't like to give up'

The mRNA vaccines developed against COVID-19 owe a lot to the work of Robert Langer, a pioneer in the delivery of mRNA. Langer, who is the Massachusetts Institute of Technology David H. Koch Institute Professor and director of the Langer Lab, helped lay the foundation for the underlying delivery mechanism…

The Independent UK

Pass urgent COVID funding or more will die, White House says

After two years at the front of the line for COVID-19 vaccines and treatments, the U.S. could soon have to begin taking a number

1 … 24 25 26 27

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.